摘要
急性早幼粒细胞白血病(acute promyelocytic leukemia,APL)是一种有着特异基因与染色体核型改变的特殊类型急性髓系白血病(acute myeloid leukemia,AML),占儿童急性髓系白血病的10%[1]。APL的发病机制相对较明确,已有相关文献阐明[2-6]。APL临床表现与AML相同,但起病及治疗过程中容易发生出血和栓塞,10%~20%的患者死于早期出血。近年来,口服复方黄黛片(realgarindigo naturalis formula,RIF)代替静脉亚砷酸治疗APL得到临床的应用和肯定,不仅可以获得相当的缓解率、复发率及生存率,还可以显著缩短住院时间。
作者
贺雏椀(综述)
于洁(审校)
He Chuwan;Yu Jie(Children’s Hospital of Chongqing Medical University,Ministry of Education Key Laboratory of Child Development and Disorders,National Clinical Research Center for Child Health and Disorders,China International Science and Technology Cooperation Center of Child Development and Critical Disorders,Chongqing Key Laboratory of Child Nutrition and Health,Chongqing 400014,China)
出处
《儿科药学杂志》
CAS
2022年第8期54-57,共4页
Journal of Pediatric Pharmacy
